
Robert W Siegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2793916/publications.pdf Version: 2024-02-01



POREDT W SIECEL

#	Article	IF	CITATIONS
1	Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nature Biotechnology, 2003, 21, 163-170.	17.5	462
2	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	6.4	287
3	Molecular Evolution of Antibody Affinity for Sensitive Detection of Botulinum Neurotoxin Type A. Journal of Molecular Biology, 2005, 351, 158-169.	4.2	135
4	Yeast display of antibody fragments: a discovery and characterization platform. Journal of Immunological Methods, 2004, 290, 69-80.	1.4	134
5	Yeast mating for combinatorial Fab library generation and surface display. FEBS Letters, 2004, 564, 24-34.	2.8	95
6	Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expression and Purification, 2005, 42, 255-267.	1.3	88
7	Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. Journal of Lipid Research, 2020, 61, 1203-1220.	4.2	88
8	Antibodies in proteomics II: screening, high-throughput characterization and downstream applications. Trends in Biotechnology, 2003, 21, 312-317.	9.3	57
9	Directed evolution for the development of conformation-specific affinity reagents using yeast display. Protein Engineering, Design and Selection, 2005, 18, 527-536.	2.1	55
10	Using an in vivo phagemid system to identify non-compatible loxP sequences. FEBS Letters, 2001, 505, 467-473.	2.8	53
11	Antibodies in proteomics I: generating antibodies. Trends in Biotechnology, 2003, 21, 275-281.	9.3	50
12	Using an in vivo phagemid system to identify non-compatible loxP sequences. FEBS Letters, 2001, 499, 147-153.	2.8	45
13	High efficiency recovery and epitope-specific sorting of an scFv yeast display library. Journal of Immunological Methods, 2004, 286, 141-153.	1.4	43
14	ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. Journal of Lipid Research, 2021, 62, 100068.	4.2	42
15	Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis and Cartilage, 2010, 18, 1150-1158.	1.3	37
16	The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein. Cell Reports, 2020, 33, 108454.	6.4	37
17	Flow Cytometric Screening of Yeast Surface Display Libraries. , 2004, 263, 311-332.		33
18	Antibody Affinity Optimization Using Yeast Cell Surface Display. Methods in Molecular Biology, 2009, 504, 351-383.	0.9	28

ROBERT W SIEGEL

4

#	Article	IF	CITATIONS
19	Affinity Maturation of Tacrolimus Antibody for Improved Immunoassay Performance. Clinical Chemistry, 2008, 54, 1008-1017.	3.2	25
20	Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics 1 1Edited by I. Wilson. Journal of Molecular Biology, 2000, 302, 285-293.	4.2	23
21	A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon. Clinical Biochemistry, 2012, 45, 1640-1644.	1.9	23
22	An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif. Journal of Lipid Research, 2022, 63, 100198.	4.2	23
23	<i>Post-hoc</i> assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. MAbs, 2020, 12, 1764829.	5.2	22
24	Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. MAbs, 2019, 11, 861-869.	5.2	20
25	A paracrine signal mediates the cell transformation response to low dose gamma radiation in JB6 cells. Molecular Carcinogenesis, 2005, 43, 31-37.	2.7	18
26	Novel sandwich immunoassays for the measurement of total and active FGF21. Bioanalysis, 2014, 6, 3283-3293.	1.5	17
27	Recombinatorial Cloning Using Heterologous Lox Sites. Genome Research, 2004, 14, 1119-1129.	5.5	16
28	Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment. AAPS Journal, 2020, 22, 68.	4.4	15
29	Angiopoietin-like protein 4 (ANGPTL4) is an inhibitor of endothelial lipase (EL) while the ANGPTL4/8 complex has reduced EL-inhibitory activity. Heliyon, 2021, 7, e07898.	3.2	15
30	Dual-Monoclonal, Sandwich Immunoassay Specific for Glucose-Dependent Insulinotropic Peptide1-42, the Active Form of the Incretin Hormone. Clinical Chemistry, 2011, 57, 849-855.	3.2	12
31	A novel, high-sensitivity and drug-tolerant sandwich immunoassay for the quantitative measurement of circulating proteins. Bioanalysis, 2012, 4, 241-248.	1.5	12
32	Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation. Analytical Biochemistry, 2012, 430, 130-137.	2.4	12
33	A Quantitative Tool to Distinguish Isobaric Leucine and Isoleucine Residues for Mass Spectrometry-Based De Novo Monoclonal Antibody Sequencing. Journal of the American Society for Mass Spectrometry, 2014, 25, 1228-1236.	2.8	8
34	Angiopoietin-like protein 4(E40K) and ANGPTL4/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4. Biochemical and Biophysical Research Communications, 2021, 534, 498-503.	2.1	8
35	Predicting antigenic peptides suitable for the selection of phage antibodies. Human Antibodies, 2004, 12, 99-112.	1.5	7

36 Antibodies in Proteomics. , 2004, 248, 519-546.

#	Article	IF	CITATIONS
37	A dual-monoclonal, sandwich immunoassay specific for glucagon like peptide-19–36/7 (GLP-19–36/7). Clinical Biochemistry, 2016, 49, 897-902.	1.9	3
38	Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. Current Medical Research and Opinion, 2021, 37, 1769-1778.	1.9	3
39	Application of a novel drug-tolerant target assay for measuring target engagement when only one epitope remains after therapeutic antibodies bind their targets. Journal of Immunological Methods, 2021, 489, 112916.	1.4	1